Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML
Asciminib Could Be New Option For Resistant Patients
Executive Summary
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.
You may also be interested in...
Novartis Builds On Its Legacy With Scemblix Approval For CML
US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.
Keeping Track: US FDA Approves Novartis’ Scemblix; Lilly Submits Tirzepatide, Withdraws Tanezumab
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.